PDXGEM: patient-derived tumor xenograft-based gene expression model for predicting clinical response to anticancer therapy in cancer patients.

In the combination therapy cohort, we observed a significant trend of a lower score toward an enhanced survival (Tarone’s trend test P = 0.03; median OS = 41, 22, and 20 months for high-, intermediate-, and low-score strata, respectively; see Fig. 5 c).

also in 9,775 other papers

We observed a borderline significant difference in prediction scores between 12 patients with pCR and 13 patients with RD after treatment with trastuzumab (AUC = 0.712, P = 0.074).

also in 11,409 other papers